AdobeStock_240748798.jpeg

We offer scalable cGMP solutions for
life science companies seeking to secure and grow their biomanufacturing capacity.
 

Accelerating Speed to Market Through High-Performance Shell

GeneSuites is introducing a new cGMP manufacturing solution to remove barriers for life science companies ready to manufacture life-changing therapies.

 

Through its High-Performance Shell (“HPS”), GeneSuites makes possible the availability of biomanufacturing capacity with greater user certainty, accelerating speed to market improvements by 18 months or greater, and increasing capital efficiencies while maximizing control over intellectual property and manufacturing process.

 

The GeneSuites Advantage

Expert
cGMP Team

Combining cGMP, financing, and real estate expertise to develop solutions that remove existing barriers for biomanufacturing

Accelerate
Speed to Market

Unprecedented approach to building flexible cGMP facilities that can easily adapt to new modalities and processes

Maximize
Quality Control

Through a hybrid approach, maintain total control of manufacturing process and environment

Secure
Intellectual Property

Maximize control of intellectual property, process, methodologies, and tech transfers

Maintain
Flexibility

Ability to accommodate multiple therapies, processes and technologies within the same facility

Leverage
Scalability

Can accommodate pre-clinical through commercial scale

GeneSuites is dedicated to building an ecosystem where cures thrive for humankind.

Experience
Building & Operating
cGMP Facilities

data-scientist-wh.png

CDMO/CMO &
Life Science
User Perspective

network-wh.png

Industry Relationships

cGMP, Lab, Construction, 
Real Estate, Capital Partners

prototype-wh.png

Real Estate Strategies
& Development

marketknowledge-wh.png

Market
Knowledge

 

Expanding Across Major Life Science Markets

GeneSuites has entered the Raleigh-Durham market with Catalyst BioCampus and will continue to expand across major life science markets in the United States and abroad.

Over 300,000 SF of purpose-built cGMP space at Catalyst is under construction and is on track to be operational by Q4 2023.

GS_Map.png
220517_Catalyst_CampusEntry_LR.jpg
Cataylst Construction Video - Oct 2022
Play Video

High-Performance Shell:
First of its Kind in North Carolina

Purpose-built cGMP Biomanufacturing Campus

In partnership with affiliates of Apollo Global Management, GeneSuites is developing Catalyst BioCampus, a three-building cGMP biomanufacturing campus located in Raleigh-Durham, NC.

Catalyst BioCampus is designed to accelerate critical manufacturing capacity for cell & gene therapy, monoclonal antibody – as well as other modalities ­– by 9-15 months. 

LOGO_Catalyst_01.png